Clinical Trials Browser

Anus Neoplasms, Condylomata Acuminata

NCT00092534 2025-08-01

FUTURE II

Phase 3 Completed

12,167 enrolled 23 charts

Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata

NCT02377999 2025-02-24

Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts

Phase 2 Completed

40 enrolled

Condylomata Acuminata

NCT03981822 2024-11-27

Condylomata Acuminata, Sexually Transmitted Diseases, Skin Diseases, Skin Diseases, Infectious, Virus Diseases, Warts, Sexually Transmitted Diseases, Viral, Skin Diseases, Viral, Papillomavirus Infections

Clinical Trials

V503-064

FUTURE II

Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts

CARE-1

Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study

Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts

ING-HPV-1

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

V503-017

Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

V501-020

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

FUTURE

Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002)

Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)

Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Glizigen-Viudid-External Anogenital Warts in Children and Adolescents

Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers

Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts

Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts

Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage

Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts

The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients